Document Detail


Prospective randomized study of an ultrashort gonadotrophin-releasing hormone agonist versus a modified suppression protocol for ovarian stimulation in intracytoplasmic sperm injection cycles.
MedLine Citation:
PMID:  9262266     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To compare oocyte quality and clinical outcome after an ultrashort or a modified suppression gonadotrophin-releasing hormone agonist (GnRHa) protocol for ovarian stimulation in intracytoplasmic sperm injection (ICSI) cycles, we conducted a prospective randomized study of 60 consecutive couples with severe male infertility admitted for their first in-vitro fertilization (IVF) and ICSI attempt. More cycles were cancelled after the ultrashort protocol (8/30) than after the modified suppression protocol (3/30), although the difference was not significant. There were no cases of severe ovarian hyperstimulation syndrome (OHSS) in the ultrashort group compared to three cases in the suppression group. The percentage of mature metaphase II oocytes recovered in both groups was similar (88 versus 86%), as were the fertilization or cleavage rates after ICSI. In the ultrashort group, a total of 64 embryos was replaced in 22 transfers (mean 2.9 embryos per transfer), resulting in three first trimester abortions and seven deliveries. In the suppression group, 11 deliveries were achieved after transfer of a total of 75 embryos in 27 patients (mean 2.8 embryos per transfer). In conclusion, there was no apparent difference between the two GnRHa protocols in terms of oocyte quality and clinical outcome. However, because of the lower rate of severe OHSS, in our study the ultrashort protocol was more appropriate for ovarian stimulation in ICSI cycles than the modified suppression protocol.
Authors:
H Strohmer; S Chatwani; F Wieser; B Danninger; A Obruca; W Feichtinger
Related Documents :
8744216 - Effects of oocyte maturation length, sperm capacitation time, and heparin on bovine emb...
10402386 - Pregnancies after activated oocyte transfer: a new option for infertility treatment.
9130906 - Successful pregnancy in a 63-year-old woman.
592286 - Fertilization and development capability of bovine follicular oocytes matured in vitro ...
16139416 - When to induce labor for post-term? a study of induction at 41 weeks versus 42 weeks.
14559726 - Tracer-derived total and folate-dependent homocysteine remethylation and synthesis rate...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  12     ISSN:  0268-1161     ISO Abbreviation:  Hum. Reprod.     Publication Date:  1997 Jul 
Date Detail:
Created Date:  1997-09-26     Completed Date:  1997-09-26     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1403-8     Citation Subset:  IM    
Affiliation:
Institute of Sterility Treatment, Department of Obstetrics and Gynaecology, University of Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Buserelin / administration & dosage*
Embryo Transfer
Female
Fertilization in Vitro / methods*
Humans
Infertility, Male / therapy*
Male
Microinjections*
Middle Aged
Ovarian Hyperstimulation Syndrome / etiology
Ovulation Induction* / adverse effects
Pregnancy
Prospective Studies
Chemical
Reg. No./Substance:
57982-77-1/Buserelin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An artificially induced follicle stimulating hormone surge at the time of human chorionic gonadotrop...
Next Document:  Prolonged inhibition of normal ovarian cycles in the rat and cynomolgus monkeys following a single s...